文献速递膀胱癌与上尿路尿路上皮癌

整块切除与传统经尿道膀胱肿瘤切除术:单中心前瞻性随机非劣效性试验

En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial.
PubMed 文献 · Eur Urol Oncol · 2022-05-23

这项单中心前瞻性随机非劣效性试验(NCT04712201)纳入300例膀胱癌患者,按1:1.5随机分配至整块切除(ERBT)组和传统经尿道膀胱肿瘤切除术(cTURBT)组。结果显示,ERBT在最终组织学中逼尿肌存在率方面非劣于cTURBT(94% vs 95%,p=0.8),且ERBT的T1亚分期可行性显著更高(100% vs 80%,p=0.02)。

要点

  • ERBT在逼尿肌存在率方面非劣于cTURBT(94% vs 95%,p=0.8)。
  • ERBT的T1亚分期可行性显著高于cTURBT(100% vs 80%,p=0.02)。
  • 两组并发症率、术后辅助治疗率、导尿时间和住院时间相当(p>0.05)。

核心结论

  • ERBT在膀胱癌分期方面非劣于cTURBT。
  • ERBT的T1亚分期可行性显著高于cTURBT。

研究设计与样本

  • 前瞻性、随机、非劣效性试验(NCT04712201),纳入诊断为膀胱癌并接受内镜干预的患者。
  • 纳入标准为肿瘤大小≤3 cm、病灶数三个或更少、无肌层浸润和/或输尿管受累迹象。
  • 按1:1.5分配比例随机,共300例受试者分配至ERBT组,非劣效界值为膀胱癌分期率5%(α风险2.5%;β风险20%)。
  • 2018年4月至2021年6月,300例患者符合纳入标准;其中248例(83%)接受了分配干预:108例(44%)接受cTURBT,140例(57%)接受ERBT。

主要发现

  • ERBT的逼尿肌存在率非劣于cTURBT(94% vs 95%;p=0.8)。
  • T1亚分期可行性在cTURBT组为80%,在ERBT组为100%(p=0.02)。
  • 两组并发症率、术后辅助治疗率、导尿时间和住院时间相当(p>0.05)。
  • 中位随访15个月(四分位距7-28)时,复发率cTURBT组为18%,ERBT组为13%(p=0.16)。

局限性

  • 局限性包括单中心高容量机构。
  • 局限性包括短期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It has been proposed that en bloc resection of bladder tumor (ERBT) improves the quality of tumor resection. A recent international collaborative consensus statement on ERBT underlined the lack of high-quality prospective studies precluding the achievement of solid conclusion on ERBT. OBJECTIVE: To compare conventional transurethral resection of bladder tumor (cTURBT) and ERBT. DESIGN, SETTING, AND PARTICIPANTS: This study (NCT04712201) was a prospective, randomized, noninferiority trial enrolling patients diagnosed with bladder cancer (BC) undergoing endoscopic intervention. Inclusion criteria were: tumor size ≤3 cm, three or fewer lesions, and no sign of muscle invasion and/or ureteral involvement. For a noninferiority rate in BC staging of 5% (α risk 2.5%; β risk 20%), a total of 300 subjects were randomized to ERBT treatment at a 1:1.5 allocation ratio. INTERVENTION: TURBT and ERBT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the presence of detrusor muscle at final histology. Secondary outcomes include BC staging, T1 substaging, artifacts, complications, the rate of adjuvant treatment, and oncological outcomes. RESULTS AND LIMITATIONS: From April 2018 to June 2021, 300 patients met the inclusion criteria. Of these, 248 (83%) underwent the assigned intervention: 108 patients (44%) underwent cTURBT and 140 (57%) underwent ERBT. The rate of detrusor muscle presence for ERBT was noninferior to that for TURBT (94% vs 95%; p = 0.8). T1 substaging was feasible in 80% of cTURBT cases versus 100% of ERBT cases (p = 0.02). Complication rates, rates of postoperative adjuvant treatment, catheterization time, and hospital stay were comparable between the two groups (p > 0.05). The recurrence rate at median follow-up of 15 mo (interquartile range 7-28) was 18% for cTURBT versus 13% for ERBT (p = 0.16). Limitations include the single high-volume institution and the short-term follow-up. CONCLUSIONS: Our study has the highest level of evidence for comparison of ERBT versus TURBT. ERBT was noninferior to TURBT for BC staging. The rate of T1 substaging feasibility was significantly higher with ERBT. PATIENT SUMMARY: We compared two techniques for removing tumors from the bladder. The en bloc technique removes the tumor in one piece and is not inferior to the conventional method in terms of the quality of the surgical resection and cancer staging assessment.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gallioli A, Diana P, Fontana M, et al. En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial. Eur Urol Oncol. 2022. PMID: 35618567. doi:10.1016/j.euo.2022.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。